Cidara Therapeutics (CDTX)
NASDAQ:CDTX
Holding CDTX?
Track your performance easily

Cidara Therapeutics (CDTX) Income Statement

719 Followers

Cidara Therapeutics Income Statement

Last quarter (Q3 2024), Cidara Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Cidara Therapeutics's net income was $-15.98M. See Cidara Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 21.48M$ 63.91M$ 64.45M---
Cost of Revenue
$ 387.00K-----
Gross Profit
$ 15.85M$ 4.33M$ 64.45M---
Operating Expense
$ 154.11M$ 88.39M$ 97.95M$ 91.83M$ 83.92M$ 62.64M
Operating Income
$ -132.62M$ -24.48M$ -33.50M$ -42.26M$ -71.85M$ -41.72M
Net Non Operating Interest Income Expense
$ 4.61M$ 2.00M$ 191.00K$ -212.00K$ -262.00K$ 221.00K
Other Income Expense
$ -17.19M$ -59.57M$ -64.45M$ -49.57M$ -12.07M$ -21.32M
Pretax Income
$ -128.01M$ -22.49M$ -33.31M$ -42.47M$ -72.11M$ -41.10M
Tax Provision
$ 200.00K$ 443.00K$ 272.00K$ -1.43M$ -469.00K$ -1.90M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -125.69M$ -22.93M$ -33.58M$ -42.47M$ -74.87M$ -41.09M
Basic EPS
$ -24.81$ -0.26$ -8.60$ -16.20$ -36.00$ -1.41
Diluted EPS
$ -24.81$ -0.26$ -8.60$ -16.20$ -36.00$ -1.41
Basic Average Shares
$ 105.92M$ 87.43M$ 3.49M$ 2.62M$ 2.08M$ 29.09M
Diluted Average Shares
$ 105.92M$ 87.43M$ 3.49M$ 2.62M$ 2.08M$ 29.09M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 154.11M$ 88.39M$ 97.95M$ 91.83M$ 83.92M$ 62.64M
Net Income From Continuing And Discontinued Operation
$ -125.69M$ -22.93M$ -33.58M$ -42.47M$ -72.11M$ -41.09M
Normalized Income
$ -117.67M--$ -43.89M--
Interest Expense
------
EBIT
$ -125.46M$ -22.49M$ -33.50M$ -42.26M$ -71.85M$ -41.10M
EBITDA
$ -124.26M$ -21.22M$ -33.36M$ -42.26M$ -70.80M$ -40.72M
Currency in USD

Cidara Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis